Most seminal studies evaluating the effect of SGLT2 inhibitors on calcium–phosphate metabolism in patients with chronic kidney disease were conducted only in patients with type 2 diabetes [23,24,25,26]. This evidence concerns the gene SLC5A2 and chronic kidney disease.